A log-rank test comparing high and low ATF3 expression groups within glioma samples revealed that high ATF3 expression was associated with poorer overall survival (Logrank_P = 8.76E-19; hazard ratio = 2.15 (1.81–2.56) (Fig. S2C). This evidence concerns the gene ATF3 and central nervous system cancer.